2020 Annual Eric Dostie Memorial College Scholarship Winners
Press Release for September 28, 2020 - Download
TEMECULA, Calif. – Nufactor®, a specialty infusion company and subsidiary of FFF Enterprises, Inc., announces its 2020 scholarship recipients. The scholarship program annually grants 10 awards of $1,000 to qualifying students with hemophilia who can best demonstrate scholastic achievement, community service and financial need.
Congratulations to our 2020 Eric Dostie Memorial College Scholarship recipients:
- Ashley Holland
- Duncan Powell
- Kealy Boyd
- Kyle Compton
- Lilly Tignor
- Luke McCann
- Olivia Hoff
- Rebecca Cox
- Shelby Carroll
The scholarship was created to honor the memory of 5-year-old Eric Dostie, a boy with hemophilia who was tragically murdered on August 27, 1994. Awards will provide financial assistance to students who either have hemophilia or a similar bleeding disorder, or who have a family member with a bleeding disorder. Students must be citizens of the United States, and enrolled full-time in an accredited two- or four-year college program.
Patrick M. Schmidt, chief executive officer of FFF Enterprises, said, "Eric Dostie continues to be an inspiration to the hemophilia community. As a child, he dreamed of becoming a scientist to invent a cure for hemophilia and we are pleased to honor Eric by supporting those who choose to pursue a college degree to broaden their education and career opportunities."
As part of the application process, applicants submitted an essay describing how his or her education will be used to serve humankind and to encourage self-improvement and enrichment.
Applications for the 2021 Eric Dostie Memorial College Scholarship will open in November 2020. Visit the Nufactor Eric Dostie Memorial College Scholarship website to learn more about the program.
About Nufactor, Inc.
Nufactor, Inc. is a specialty infusion company and a subsidiary of FFF Enterprises, Inc., the largest and most trusted distributor of plasma products, vaccines, biosimilars and other specialty pharmaceuticals and biopharmaceuticals. Nufactor, established in 1995, specializes in the treatment of patients with chronic conditions, with concentration on treating rare disease states in neurology, immunology, hematology, oncology, dermatology and rheumatology. The company also supports the immune globulin community through IG Living magazine, a publication devoted to promoting patient advocacy, education and communication. Nufactor is dedicated to solving the chronic problems of affordability, availability and safety in disease state management for chronically ill patients. Nufactor is deeply committed to the philosophy of providing philanthropic support to the patient communities they serve, including hemophilia, immune deficiencies and peripheral neuropathies, among others.
About FFF Enterprises, Inc
FFF Enterprises, Inc., founded in 1988, is a multi-billion-dollar organization that continues to celebrate more than 30 years of business, and a flawless safety track record for product distribution. FFF has taken a leadership position regarding supply chain safety and innovation, setting new standards and pioneering industry firsts. FFF's commitment to Guaranteed Channel Integrity® ensures that products are purchased only from the manufacturer and shipped only to licensed healthcare providers, with additional steps taken to safely store, handle and ship products to ensure patient safety is never compromised. Their proprietary system Lot-Track™, provides verification of this secure channel, BioSupply® online ordering system offers an easy-to-use and convenient platform to order products, and MyFluVaccine® is an unprecedented vaccination program that has added a new level of safety, convenience and reliability to both healthcare providers and patients. Through their Forward-Deployed Inventory programs MinibarRx® and Verified Inventory Program (VIPc)®, FFF has revolutionized product inventory management solutions for the industry. Trust in their services is assured through Costparency™ — FFF's promise to healthcare providers that they will not engage in deceptive pricing tactics.